Pancreatic Cancer Trial Shows Doubled Survival with New Drug Combination
A phase II trial found elraglusib combined with chemotherapy doubled one-year survival and reduced death risk by 38% for pancreatic cancer patients.
Key Points
- Elraglusib combined with chemotherapy doubled one-year survival
- Reduced risk of death by 38% for pancreatic cancer patients
- Phase II trial published in Nature Medicine
- Led by Northwestern University professor
Full Details
A phase II randomized trial published in Nature Medicine demonstrated that elraglusib, when combined with chemotherapy, doubled one-year survival rates for pancreatic cancer patients and reduced the risk of death by 38%. The study, led by Professor Devalingam Mahalingam of Northwestern University Feinberg School of Medicine, offers cautious optimism for treating one of the most challenging solid tumors. Pancreatic cancer has historically had poor prognosis, making these findings particularly significant for patients and oncologists. The trial results suggest a potential new standard of care that could improve outcomes for a disease with limited treatment options.
Why It Matters
This breakthrough could significantly change treatment protocols for pancreatic cancer, offering new hope for patients with historically poor survival rates.
Get stories like this delivered daily
AI-curated news, personalized to your interests. Zero noise.
Start 7-Day Free Trial →More in Global News
US singer D4vd charged with murder stemming from death of missing teenage girl
Prosecutors say the singer, real name David Anthony Burke, could face life in prison due to the nature of the case.
Ukrainian drone attack hits Russia’s Tuapse port
Plumes of black smoke were seen after Ukrainian drones targeted Russia’s Black Sea port of Tuapse.
Iranian Envoy Summoned After Revolutionary Guards Fire On Indian Ships
The ships -- Indian-flagged cargo vessels - were fired on in the Strait of Hormuz on April 18. The incident occurred due to a communication gap between the Iranian government and the local unit of the Revolutionary Guard, sources said.
‘Israel never talked me into the war with Iran,’ Trump says
President Donald Trump posted on Truth Social that Israel never talked him into a war with Iran, pushing back against news reports and right-wing commentators who suggested Israeli Prime Minister Benjamin Netanyahu influenced his decisions. He wrote that the October 7th attack reinforced his lifelong opinion that Iran can never have a nuclear weapon. Trump also claimed that "the results in Iran will be amazing" and suggested that if Iran's new leaders are "smart," the country could have a great